

DAFTAR PUSTAKA

1. Global Borden of Cancer (GLOBOCAN). The Global Cancer Observatory. International Agency for Research on Cancer. 2022.
2. Zaini J, Syahrudin E, Andarini SL. Kanker Paru Karsinoma Bukan Sel Kecil. Dalam: Rasmin M, Jusuf A, Amin M, Taufik, Nawas A, Bagus IN, dkk, penyunting. Buku Ajar Pulmonologi dan Kedokteran Respirasi. Buku 2. Jakarta: Universitas Indonesia, 2017. h. 9-22.
3. Supartono, Suryanto A. Faktor - faktor yang Mempengaruhi Ketahanan Hidup Satu Tahun Penderita Kanker Paru Stadium Lanjut di RSUP Dr. Kariadi Semarang. Med Hosp. 2012;1(1):25-31.
4. Megasari A, Bagiada M. Ketahanan Hidup 1 Tahun Karsinoma Paru di Divisi Pulmonology RSUP Sanglah Denpasar. MEDICINA. 2020;51(1):1-5.
5. Bethesda. SEER Cancer Stat Facts: Lung and Bronchus Cancer. National Cancer Institute. <https://seer.cancer.gov/statfacts/html/lungb.html>
6. Frank MS, Bodtger U. An Individual Approach to Comorbidities in Lung Cancer. J Thorac Oncol. 2023;18(3):254-5.
7. Miura N, Shoji F, Kozuma Y, Toyokawa G, Yamazaki K, Takeo S. Preoperative Immune-Nutritional Abnormality Predicts Poor Outcome in Elderly Non-Small-Cell Lung Cancer Patients with Comorbidities. J Thorac Cardiovasc Surg. 2020;26(5):240-7.
8. Dima S, Chen KH, Wang KJ, Wang KM, Teng NC. Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-based Cohort Study in Taiwan. Biomed Res Int. 2018;2018:1252897.
9. Majeed H, Zhu H, Williams SA, Hamann HA, Natchimuthu VS, Lee J, et al. Prevalence and Impact of Medical Comorbidities in a Real-World Lung Cancer Screening Population. J Clin Lung Cancer. 2022;23(5):419-27.
10. World Health Organization. Estimated Cancer Incidence and Mortality and Prevalence Worldwide in 2021 [Internet]. International Agency for Research on Cancer. 2021 [cited 2021 jun 21]. Available from: <http://globocan.iarc.fr/>
11. Syahrudin E, Pratama AD, Arief N. A Retrospective Study: Clinical and Diagnostic Characteristics in Advanced Stage of Lung Cancer Patients with Pleural Effusion in Persahabatan Hospital 2004-2007. J Respir Indo. 2020;30(3):146-51.
12. Horoweg N, Van de ACM, Thunnissen E, Nackaerst K, Weenink, C, Groen HJM, et al. Characteristic of Lung Cancers Detected by Computerized Tomography Screening in the Randomized NELSON Trial. Am J Respir Crit Care Med. 2012;187(8):848-54.
13. Leduc C, Antoni D, Charloux A, Falcoz PE, Quoix E. Comorbidities in the Management of Patients with Lung Cancer. J Respir Eur. 2017;49:1601721.
14. Jusuf A. Pengobatan Kanker Paru Menurut Konsensus Bali 2021. Dalam: Margono BP, Widjaja A, Amin M. Pertemuan Ilmiah Paru Milenium 2002. Surabaya: PDPI2022S-2.

15. Aditiawarman. Hubungan Ketahanan Hidup 1 tahun Penderita Kanker paru yang Dirawat di RS Dr. Kariadi Semarang dengan Faktor - faktor yang berhubungan. Karya Akhir PPDS I. FK UNDIP, 2003. [online]2010[cited 2010 Jun 8]; availablefrom: URL:<http://www.eprints.undip.ac.id>.
16. Falcoz PE, Conti M, Brouchet L. The Thoracic Surgery Scoring System (Thoracscore): Risk Model for in-Hospital Death in 15, 183 Patients Requiring Thoracic Surgery. *J Thorac Cardiovasc Surg.* 2007;133:325-32.
17. Powel HA, Tata LJ, Baldwin DR, Stanley RA, Khakwani A, Hubbard RB. Early Mortality After Surgical Resection for Lung Cancer: An Analysis of the English National Lung Cancer Audit. *Thorax.* 2013;68:826-34.
18. Malene S, Frank, Uffe B. An Individualized Approach to Comorbidities in Lung Cancer. *J Thoracic Oncol.* 2023;18(3):254-6.
19. Dutkowska AE, Antczak A. Comorbidities in Lung Cancer. *J Thorac Oncol.* 2016;84:186-92.
20. Serap AB, Hasim B, Sila A, Birsen M, Muge D, Ilknur B. Charlson Comorbidity Index in Predicting Poor Clinical Outcomes and Mortality in Patients with Covid-19. *J Thorac Turk.* 2022;23(2):145-53.
21. Zhao L, Leung LH, Wang J, Li H, Che J, Liu Li, et al. Association Between Charlson Comorbidity Index Score and Outcome in Patients with Stage IIIB-IV Non-small Cell Lung Cancer. *BMC Pulmonary Medicine.* 2017;17(112):1-7.
22. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic Obstructive Pulmonary Disease is Associated with Lung Cancer Mortality in a Prospective Study of Never Smokers. *Am J Respir Crit Care Med* 2007;176:285-90.
23. Raviv S, Hawkins KA, DeCamp MM, Kalhan R. Lung Cancer in Chronic Obstructive Pulmonary Disease: Enhancing Surgical Options and Outcomes. *Am J Respir Crit Care Med.* 2011;183:1138-46.
24. Iachina M, Jakobsen E, Moller H. The Effect of Different Comorbidities on Survival of Non-Small Cells Lung Cancer Patients. *Lung.* 2015;193:291-7.
25. Nastiti NP, Wulandari L, Sulistiawati S, Febriani A, Efendi WI. Prevalence of Lung Cancer with a History of Tuberculosis. *J Respi Indo.* 2023;9(2):87-92.
26. Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity and Survival in Lung Cancer Patients. *Cancer Epidemiol Biomarkers Prev.* 2015;24:1079-85.
27. Han YL, Dong L, Hao W, Zheng-Qing BA, Ying X, Yi-Lu LIU, et al. Pre-existing Cardiometabolic Comorbidities and Survival of Middle-age and Elderly Non-Small Cell Lung Cancer Patients. *J Geriatr Cardiol.* 2023;20(10):737-47.
28. Herrero RD, Nieto-Guerrero GJM, Cacicedo FDB. Cardiovascular Disease and Survival in Non-Small Cell Lung Cancer: A Multicenter Prospective Assessment. *Clin Transl Oncol.* 2019;21:1220-30.
29. Motoyasu K, Takehito S, Keita M, Ryota K, Yuichiro H, Yuta N, et al. Cerebral Infarction in Advanced Non-Small Cell Lung Cancer: A Case Control Study. *BMC Cancer.* 2016;16:203-11.

30. You L, Yaohua H, Yi Z, Shuanshuan X, Changhui W. Impact of Type 2 Diabetes Melitus on the Prognosis of Non-Small Cell Lung Cancer. *J Clin Med*. 2023;12(1):321-32.
31. Siegel RL, Miller KD, Fuchs, HE, Jemal A. Cancer Statistics. 2021. *Ca Cancer J. Clin*. 2021;71:7-33.
32. Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-Specific Mortality in Chronic Kidney Disease: Longitudinal Follow-up of a Large Cohort. *Clin J Am Soc Nephrol*. 2011;6:1121-8.
33. Kim T, Kim SH, Choi H, Shin TR, Kim HI, Jang SH, et al. Clinical Prognosis of Lung Cancer in Patients with Moderate Chronic Kidney Disease. *J Cancers*. 2022;14:4786-98.
34. Ming SL, Hung-I L, Tzu-Ping C, Chen-Chie C, Tsung-Ming Y, Miao-Fen C. Survival of Patients with Lung Cancer in the Setting of Liver Cirrhosis: A multicenter Propensity Score Matching Study. *J Thorac Cardiovasc Sugr*. 2021;13:4373-81.
35. Metwally EM, Patricia R, Danielle DD, Lindsay L, Pasangi P, Derek L, et al. Lung Cancer Screening in Individual with and without Lung-Related Comorbidities. *J Thorac Oncol*. 2022;5(9):1-11.
36. Timothy RA, Ding K, Seymour L. Age and Comorbidity as Independent Prognostic Factors in the Treatment on Non-Small Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trial Group Trials. *Journal of Clinical Oncology*. 2008;26:54-9.
37. Ikhsan B. Hubungan Faktor Risiko dengan Kesintasan Kanker Paru Jenis Karsinoma Bukan Sel Kecil Stadium Lanjut. Tesis. Makasar: Departemen Pulmonologi dan Kedokteran Respirasi FK UNHAS, 2022.
38. Vadire Y, Kalvapudi S, Yendamuri S. Obesity and Lung Cancer: A Narrative Review. *J Thorac Dis*. 2023;15(5):2806-23
39. Chauaid A, Debieuvre D, Durand I, Zaleski I, Fernandes J, Scherpereel A et al. Survival Inequalities in Patients with Lung Cancer in France: A Nationwide Cohort Study (the TERRITOIRE study). *Plos One*. 2017;1-13.
40. Goud S, Mohapatra PR, Bhuniya S, Majumdar SK, Mishra P, Panigrahi MK, et al. Impact of Comorbidity Scores on the Overall Survival of Patients with Advanced Non-small Cell Lung Cancer: A Real-World Experience from Eastern India. *Cureus*. 2022;14(10):e30589.
41. Gendarme S, Irajizad E, Long JP, Fahrman JF, Dennison JB, Ghasemi SM, et al. Impact of Comorbidities on the Mortality Benefits of lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials. *J Thocic Oncol*. 2025:1-10.
42. Pulvers K, Scheuermann TS, Romero DR, Basora B, Luo X, Ahluwalia JS. Classifying a Smoker Scale in Adult Daily and Nondaily Smokers. *Nicotine Tob Res* 2014; 16: 591-9.
43. Syahrudin E, Zaini J, Soehardiman D, Anwidyaningsih W, Icksan AG, Mety SH et al. Pedoman Penstagingan dan Pengevaluasian Hasil Terapi di Indonesia. Perhimpunan Dokter Paru Indonesia: Jakarta, 2019.
44. Crooks, V, Waller S et al. The use of Karnofsky Performance Scale in Determining Outcomes and Risk in Geriatric Outpatients. *J Gerontol*. 1991:139-44.

45. Sinaga FTY, Oktobiannobel J, Soemarwoto RAS, Yunanda V. Gambaran Progresivitas dan Prognosis Pada Pasien CA Paru di RSUD Dr. H. Abdul Moeloek Provinsi Lampung Tahun 2018-2021. *Medula*. 2022;12:336-41.
46. Sigel K, Wisnivesky JP. Comorbidity Profiles of Patients with Lung Cancer: A New Approach to Risk Stratification. *AnnalsATS*. 2017;14(10):1512-13.
47. Fowler H, Belot A, Ellis L, Maringe C, Fernandez MAL, Njagi EN, et al. Comorbidity Prevalence Among Cancer Patients: A Population-Based Cohort Study of Four Cancers. *BMC Cancer*. 2020;20(2):1-15.
48. Otin CL, Blasco MA, Patridge L, Serrano M, Kroemer G. Hallmarks of Aging: An Expanding Universe. *Cell*. 2023;186(2):243-78.
49. Au PC, Lee AW, Lee VH, Wong IC, Hui RY, Cheung CL. The Trends in Lung Cancer Prevalence, Incidence and Survival in Hong Kong Over the Past Two Decades (2002–2021): A Population-Based Study. *Lancet Reg Heal West Pac* 2024; 45: 1–13.
50. Marcus MW, Chen Y, Duffy SW, Field JK. Impact of Comorbidity on Lung Cancer Mortality - A Report from the Liverpool Lung Project. *Oncology Letters*. 2015;9:1902-6.
51. Zimmermann J, Walter J, Stoleriu MG, Kovacs J, Yavuz G, Damirov F, et al. The Impact Comorbidities on The All-Cause Mortality of Surgical Treated Non-Small Cell Lung Cancer Patients - Visualization with The Aid of a Comorbidome. *BMC Surg*. 2025;25(285):1-11.
52. Temmemagi CM, Dudas CN, Simoff M, Kvale P. In Lung Cancer Patients, Age, Race-ethnicity, Gender, and Smoking Predict Adverse Comorbidity, Which in Turn Predicts Treatment and Survival. *J Clin Epidemiol*. 2004;57(6):597-609.
53. Hernandez D, Cheng CY, Hernandez VK, Schlander M. Survival and Comorbidities in Lung Cancer Patients; Evidence from Administrative Claims Data in Germany. *Oncol Res*. 2023;30(4):173-85.
54. Buja A, Di Pumpo M, Rugge M, Zorzi M, Rea F, Pantaleo I, et al. Patterns of Comorbidities in Lung Cancer Patients and Survival. *Cancers (Basel)*. 2025;17(9):1577-87.
55. Gould MK, Munoz PCE, Hahn EE, Lee JS, Parry C, Shen E. Comorbidity Profiles and Their on Treatment Selection and Survival among Patients with Lung Cancer. *Ann Am Thorac Soc*. 2017;14(10):1571-80.
56. Fawziah A, Sari NK, Uyainah A, Soetandyo N, Dewiasty E. Kesintasan Satu Tahun Penderita Karsinoma Paru Bukan Sel Kecil Stadium IIIB/IV Usia lanjut yang Menjalani Kemoterapi Dibandingkan dengan Non-Kemoterapi. *Chest*. 2015;2(2):54-60.
57. Islam KMM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity and Survival in Lung Cancer Patients. *Cancer Epidemiol Biomarkers Prev*. 2015;24(7):1079-85.